The Spectranetics Corporation  

(Public, NASDAQ:SPNC)   Watch this stock  
Find more results for The Spectranetics Corp
23.58
-0.99 (-4.03%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 22.89 - 24.96
52 week 15.52 - 31.94
Open 24.17
Vol / Avg. 1.35M/513,262.00
Mkt cap 980.17M
P/E     -
Div/yield     -
EPS -0.12
Shares 41.57M
Beta 1.38
Inst. own 88%
Jun 10, 2014
Spectranetics Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
Apr 23, 2014
Q1 2014 Spectranetics Earnings Conference Call - Webcast
Apr 23, 2014
Q1 2014 Spectranetics Earnings Release
Apr 7, 2014
Q1 2014 Preliminary Spectranetics Earnings Release
Feb 27, 2014
Q4 2013 Spectranetics Earnings Conference Call - Webcast
Feb 27, 2014
Q4 2013 Spectranetics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -14.29% -0.23%
Operating margin -13.93% 0.25%
EBITD margin - 9.76%
Return on average assets -10.58% -0.23%
Return on average equity -12.01% -0.27%
Employees 575 -
CDP Score - -

Address

9965 Federal Drive
COLORADO SPRINGS, CO 80921
United States - Map
+1-719-6338333 (Phone)
+1-877-4472022 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company�s products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. It offers excimer laser system known as the CVX-300. Its Vascular Intervention business unit includes a range of peripheral and cardiac laser catheters for ablation of lockages in arteries above and below the knee and within coronary arteries; support catheters to facilitate crossing of coronary and peripheral arterial blockages; therapeutic infusion system catheters for vascular delivery of drugs and diagnostic agents, and aspiration and thrombectomy catheters for the removal of thrombus. Lead Management business unit includes excimer laser sheaths, non-laser sheaths and cardiac lead management accessories for removal of problematic pacemaker and defibrillator cardiac leads.

Officers and directors

R. John Fletcher Independent Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Scott William Drake President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Guy A. Childs Chief Financial Officer
Age: 47
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kimberly McIntosh Bridges Senior Vice President - Sales and Marketing of Vascular Intervention
Bio & Compensation  - Reuters
Donna Ford-Serbu Senior Vice President - Sales and Marketing of Lead Management
Age: 44
Bio & Compensation  - Reuters
Jason D. Hein Senior Vice President - Lead Management Sales
Age: 44
Bio & Compensation  - Reuters
Shahriar Matin Senior Vice President - Operations, Business Development and International
Age: 38
Bio & Compensation  - Reuters
Austin B. Byrd Chief Compliance Officer, Vice President
Age: 47
Bio & Compensation  - Reuters
Paul Gardon Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Robert Michael Fuchs Vice President, Global Head of Human Resources
Age: 46
Bio & Compensation  - Reuters